Logo of National Eczema Association mobile menu icon
Icon link to National Eczema's Instagram feed. Icon link to National Eczema's YouTube channel. Icon link to National Eczema's Facebook page. Icon link to National Eczema's Twitter feed. Icon link to National Eczema's inspire.com page. Search Icon to search the site

Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.
 

Search Results for “dupilumab”


Biologics

…lower or less severe inflammation and therefore fewer symptoms of atopic dermatitis. Dupixent (dupilumab) Dupixent (dupilumab) is the first biologic medication approved by the U.S. Food and Drug Administration (FDA)…

Read More


Eczema Awareness Month Kicks-Off with Groundbreaking News

…come to market as soon as spring 2017. Patients who have participated in clinical trials of dupilumab shared their stories with The New York Times in an article published today:…

Read More


Shining a Light on the Seriousness of Atopic Dermatitis and New Treatment Options

…market in 2017. The other, dupilumab, is currently being reviewed by the FDA. ICER develops its recommendations based on clinical evidence, as well as input from stakeholders including health organizations,…

Read More


Two new atopic dermatitis biologics show promising results in phase IIb clinical trials

Ever since the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab), other biologics have been making their way through clinical trials. Biologics are injectable drugs that use an antibody…

Read More


Eczema around the world

…UV therapy, immunosuppressants and antifungal medications, but nothing worked,” she said. Sousa and Troha eventually found relief with a biologic treatment when the European Union approved Dupixent (dupilumab) for treating…

Read More


It’s time for our annual treatment roundup

…but for children and adolescents as well. Ever since the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) in March 2017, it signaled the beginning of the “Golden Age…

Read More


Biologics may show greater risk for infection than systemics

…meeting of the European Academy of Dermatology and Venerology (EADV) in September 2018. The biologics analyzed did not include Dupixent (dupilumab), the only biologic currently approved by the FDA for…

Read More


Q & A: Introducing Biologics with Dr. Paul Yamauchi

In March, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab), the first biologic medication for adults with moderate to severe atopic dermatitis (AD). Unlike topical or oral medications,…

Read More


First Biologic Approved for Moderate to Severe Atopic Dermatitis

Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab), the first biologic medication for adults with moderate to severe atopic dermatitis (AD) for whom other topical treatments have not…

Read More


Understanding inflammation’s role in atopic dermatitis

…he continued. By contrast, “Dupilumab (Dupixent) is effective precisely because it targets IL-4 and IL-13, two cytokines known to drive the inflammatory response in AD.” Then, there’s the outside-inside question:…

Read More